Evaxion biotech announces pricing of $15 million public offering

Copenhagen, denmark, feb. 01, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today announced the pricing of a public offering of an aggregate of 3,750,000 of its american depositary shares (“adss”) (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 adss at a combined public offering price of $4.00 per ads (or pre-funded warrant in lieu thereof) and accompanying warrant. msd global health innovation fund (msd ghi), a corporate venture capital arm of merck & co., inc., rahway, nj, usa, who became an evaxion shareholder in december 2023, is also participating in this offering. the warrants will have an exercise price of $4.00 per ads, will be exercisable immediately upon issuance and will expire five years following the date of issuance. each ads represents ten ordinary shares of the company. the closing of the offering is expected to occur on or about february 5, 2024, subject to the satisfaction of customary closing conditions.
EVAX Ratings Summary
EVAX Quant Ranking